169 related articles for article (PubMed ID: 22777834)
21. Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.
Burrell JS; Walker-Samuel S; Baker LC; Boult JK; Jamin Y; Ryan AJ; Waterton JC; Halliday J; Robinson SP
Int J Cancer; 2012 Oct; 131(8):1854-62. PubMed ID: 22290271
[TBL] [Abstract][Full Text] [Related]
22. Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.
Dorow DS; Cullinane C; Conus N; Roselt P; Binns D; McCarthy TJ; McArthur GA; Hicks RJ
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):441-52. PubMed ID: 16450138
[TBL] [Abstract][Full Text] [Related]
23. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
[TBL] [Abstract][Full Text] [Related]
24. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
Najy AJ; Jung YS; Won JJ; Conley-LaComb MK; Saliganan A; Kim CJ; Heath E; Cher ML; Bonfil RD; Kim HR
Prostate; 2012 Sep; 72(12):1328-38. PubMed ID: 22213159
[TBL] [Abstract][Full Text] [Related]
25. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.
Uhl M; Saueressig U; van Buiren M; Kontny U; Niemeyer C; Köhler G; Ilyasov K; Langer M
Invest Radiol; 2006 Aug; 41(8):618-23. PubMed ID: 16829744
[TBL] [Abstract][Full Text] [Related]
26.
Zhang MY; Zhang RJ; Jiang HJ; Jiang H; Xu HL; Pan WB; Wang YQ; Li X
Hepatobiliary Pancreat Dis Int; 2019 Apr; 18(2):164-172. PubMed ID: 30850340
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
28. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
[TBL] [Abstract][Full Text] [Related]
29. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
[TBL] [Abstract][Full Text] [Related]
30. Quantitative correlation at the molecular level of tumor response to docetaxel by multimodal diffusion-weighted magnetic resonance imaging and [¹⁸F]FDG/[¹⁸F]FLT positron emission tomography.
Honndorf VS; Schmidt H; Wehrl HF; Wiehr S; Ehrlichmann W; Quintanilla-Martinez L; Barjat H; Ricketts SA; Pichler BJ
Mol Imaging; 2014; 13():. PubMed ID: 25430886
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of [
Jiang H; Zhang R; Jiang H; Zhang M; Guo W; Feng G; Pan W; Xu H; Wang S
Nucl Med Biol; 2019; 72-73():36-44. PubMed ID: 31330410
[TBL] [Abstract][Full Text] [Related]
32. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.
di Tomaso E; Snuderl M; Kamoun WS; Duda DG; Auluck PK; Fazlollahi L; Andronesi OC; Frosch MP; Wen PY; Plotkin SR; Hedley-Whyte ET; Sorensen AG; Batchelor TT; Jain RK
Cancer Res; 2011 Jan; 71(1):19-28. PubMed ID: 21199795
[TBL] [Abstract][Full Text] [Related]
33. Increase in tumour permeability following TGF-beta type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI.
Minowa T; Kawano K; Kuribayashi H; Shiraishi K; Sugino T; Hattori Y; Yokoyama M; Maitani Y
Br J Cancer; 2009 Dec; 101(11):1884-90. PubMed ID: 19888220
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
Kendrew J; Odedra R; Logié A; Taylor PJ; Pearsall S; Ogilvie DJ; Wedge SR; Jürgensmeier JM
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1021-32. PubMed ID: 23355042
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.
Tentler JJ; Bradshaw-Pierce EL; Serkova NJ; Hasebroock KM; Pitts TM; Diamond JR; Fletcher GC; Bray MR; Eckhardt SG
Clin Cancer Res; 2010 Jun; 16(11):2989-2998. PubMed ID: 20406842
[TBL] [Abstract][Full Text] [Related]
36. Conversion of arterial input functions for dual pharmacokinetic modeling using Gd-DTPA/MRI and 18F-FDG/PET.
Poulin E; Lebel R; Croteau E; Blanchette M; Tremblay L; Lecomte R; Bentourkia M; Lepage M
Magn Reson Med; 2013 Mar; 69(3):781-92. PubMed ID: 22570280
[TBL] [Abstract][Full Text] [Related]
37. A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment.
Boult JK; Terkelsen J; Walker-Samuel S; Bradley DP; Robinson SP
PLoS One; 2013; 8(4):e63024. PubMed ID: 23638177
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the diagnostic accuracy of diffusion-weighted and dynamic contrast-enhanced MRI with
Diez AIG; Fuster D; Morata L; Torres F; Garcia R; Poggio D; Sotes S; Del Amo M; Isern-Kebschull J; Pomes J; Soriano A; Brugnara L; Tomas X
Eur J Radiol; 2020 Nov; 132():109299. PubMed ID: 33032207
[TBL] [Abstract][Full Text] [Related]
39. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
40. The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.
Honndorf VS; Schmidt H; Wiehr S; Wehrl HF; Quintanilla-Martinez L; Stahlschmidt A; Barjat H; Emmas SA; Pichler BJ
Mol Imaging Biol; 2016 Apr; 18(2):249-57. PubMed ID: 26276154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
